Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Buoyed By US Tax Reform, Merck Plans $12bn In Capital Investments

Executive Summary

Keytruda had a great year in 2017 with $3.8bn in sales, but some Merck investors would like to see more M&A activity to bolster the company's pipeline, relaxing dependency on the blockbuster PD-1 inhibitor. However, the company revealed $12bn in capital investments to support planned growth.


Related Content

Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer
J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's
Lynparza Poised For Growth With Broad Ovarian Cancer Approval
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts